Versantis AG received USFDA approval for VS-01 for the Treatment of Urea Cycle Disorders


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Versantis AG received USFDA approval for VS-01 for the Treatment of Urea Cycle Disorders
Versantis receives US FDA rare pediatric disease designation for VS-01 for the treatment of urea cycle disorders

Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, announced that the U.S. Food and Drug Administration (FDA) has granted a rare pediatric disease designation (RPDD) to its lead product candidate VS-01, an ammonia clearance enhancer, for the treatment of Urea Cycle Disorders (UCD). UCD is a rare and life-threatening condition caused by an inherited inborn error of metabolism. Current treatment options are associated with poor outcomes.

“The rare pediatric disease designation highlights the potential of using VS-01 to treat the serious and life-threatening manifestations of UCD,” said Meriam Kabbaj, Chief Operations Officer and Co-founder of Versantis. “It is valuable recognition that will help Versantis to ramp up its pediatric program by fostering collaborations with key opinion leader and patients’ associations.”

The FDA grants rare pediatric disease designation for serious or life-threatening diseases primarily affecting children from birth to 18 years and affecting fewer than 200,000 people in the USA. Upon approval of a new drug application, the RPDD renders sponsor companies eligible for a priority review voucher, which can be redeemed to obtain accelerated FDA review of a drug candidate, is any indication, potentially gaining early market access. This voucher may be sold or transferred to another sponsor.

Versantis recently completed a $16M Series B financing round and is currently raising new funds to fuel VS-01 clinical development in rare indications, including UCD.

“This recognition acknowledges the unmet medical needs of children with UCD. Importantly, with this designation, we may qualify to receive a priority review voucher from FDA, at the time of marketing approval of VS-01. It provides significant value to our current effort to develop effective treatments for this devastating rare disease,” said Vincent Forster, Versantis’ Co-founder and CEO.

VS-01 is an innovative liposomal-based detoxification therapy that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during liver and kidney failures. More specifically, VS-01 clears ammonia from the body, which is the main neurotoxic metabolite and can lead to brain edema. With its rapid onset, VS-01 could be the first-line medication of choice for acute hyperammonemia in an emergency setting. VS-01 is currently being evaluated in clinical trials in decompensated cirrhotic patients.

Urea cycle disorder is an orphan condition that predominantly affects children where patients present with hyperammonemia either shortly after birth (about 50%) or, later at any age, leading to death or to severe neurological handicap. The clinical course in newborns is characterized by an initial hyperammonemic crisis shortly after birth progressively leading to somnolence, lethargy, coma and death. In hyperammonemic crises, dialysis is used to drastically lower ammonia levels, however, it can only be performed in highly specialized tertiary centres and is often initiated too late. Up to 90% of newborns do not survive the initial event of acute hyperammonemia or suffer from severe neurological sequelae. Curative orthotopic liver transplantation can be performed in children from about 10 kg body weight. VS-01 is principally intended as bridging therapy until the children are old enough and have reached the appropriate body weight and/or until they can access a tertiary centre.

Tags : #VersantisAG #LatestUSFDAApproval19thOct #LatestPharmaNews19thOct #TreatmentofUreaCycleDisorders #MeriamKabbaj #VincentForster #OrphanLiverDiseases #LatestNewsonVersantisAG19thOct

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026